Facial erythema of rosacea

Active Ingredient: Brimonidine

Indication for Brimonidine

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Brimonidine is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.

For this indication, competent medicine agencies globally authorize below treatments:

1 application per 24 hours

For:

Dosage regimens

Cutaneous, between 0 milligrams brimonidine and 3.3 milligrams brimonidine, once daily, over the duration of 1 week. Afterwards, cutaneous, 3.3 milligrams brimonidine, once daily. The maximum allowed total dose is 3.3 milligrams brimonidine daily.

Detailed description

One application per 24 hours, at any time suitable for the patient, for as long as facial erythema is present.

The maximum daily recommended dose is 1 g of gel in total weight, which corresponds to approximately five pea sized amounts.

Treatment should be initiated with a smaller amount of gel (less than the maximum) for at least one week. The amount of gel can then be increased gradually based on tolerability and patient response.

Brimonidine gel should be applied smoothly and evenly as a thin layer across the entire face (forehead, chin, nose and both cheeks) avoiding the eyes, eyelids, lips, mouth and membrane of the inner nose. Brimonidine gel should be applied only to the face.

Dosage considerations

Hands should be washed immediately after applying the medicinal product.

Brimonidine gel can be used in conjunction with other cutaneous medicinal products for the treatment of inflammatory lesions of rosacea and with cosmetics. These products should not be applied immediately before the daily application of brimonidine gel; they may be used only after the applied brimonidine gel has dried.

Active ingredient

Brimonidine

Brimonidine is an alpha2-adrenergic receptor agonist that is 1000-fold more selective for the alpha2-adrenoceptor than the alpha1-adrenoreceptor. This selectivity results in no mydriasis and the absence of vasoconstriction in microvessels associated with human retinal xenografts.

Read more about Brimonidine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.